期刊文献+

安立生坦片的体外溶出度测定 被引量:1

The method of in vitro dissolution of ambrisentan tablets
下载PDF
导出
摘要 目的研究安立生坦片的体外溶出度测定方法。方法采用溶出度浆法,以p H5. 0醋酸盐缓冲液为溶出介质,转速50 r·min^(-1),高效液相色谱法测定,以磷酸二氢钾缓冲液-乙腈(体积比为50∶50)为流动相,色谱柱:Waters Symmetry Shield RP18(150 mm×3. 9 mm,5μm),检测波长:220 nm,柱温:40℃,流速:0. 9×10-3L·min^(-1)。结果安立生坦质量浓度在0. 56~11. 2×10-3g·L^(-1)内线性关系良好,相关系数r=0. 999 6;平均回收率(n=9)为102. 04%,RSD为0. 911%;无滤膜吸附、精密度及重现性良好。测定3批样品的溶出行为,30 min时溶出度均在85%以上。结论该方法可用于本品的溶出度检查。 Objective To establish determination method for the dissolution of ambrisentan tablets in vitro.Methods The pH5. 0 acetate buffer was used as the dissolution medium using paddle method with the rotate speed of 50 r·min-1. The result was determined by HPLC with Symmetry shields RP18( 150 mm × 3. 9 mm,5 μm microns,Waters) and potassium dihydrogen phosphate buffer-acetonitrile( 50 ∶ 50) as a mobile phase with the flowrate of 0. 9 mL·min-1. The wavelength was 220 nm and the column temperature was 40 ℃.Results The concentration of ambrisentan was linear in the range of 0. 56-11. 2 mg·L-1 and linear relationship was evaluated as y = 221. 55 x-25. 356( r = 0. 999 6). The average recovery rate of ambrisentan( n = 9) was 102. 04% with the RSD of 0. 911%. The dissolution rates of three batches of ambrisentantablets in vitro at 30 min were more than 85%. Conclusion This method is simple,reliable and accurate for the dissolution determination of ambrisentan tablets.
作者 董爽 王迷娟 李阳 王威 张猛 张颖 DONG Shuang;WANG Mijuan;LI Yang;WANG Wei;ZHANG Meng;ZHANG Ying(Peking Union Second Pharmaceutical Factory,Beijing 102600,China;Beijing Union Pharmaceutical Factory,Beijing 102600,China)
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2018年第11期917-920,共4页 Journal of Shenyang Pharmaceutical University
关键词 安立生坦片 溶出度测定 高效液相色谱法 ambrisentan tablets determination of dissolution HPLC
  • 相关文献

参考文献1

二级参考文献20

  • 1Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-asso- ciated pulmonary arterial hypertension in the modem management era[J]. Circulation, 2010, 122: 156-63.
  • 2Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation(ISHLT)[J]. Eur Heart J, 2009, 30(20): 2493-537.
  • 3Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension [J]. J Clin Invest, 2012, 122(12): 4306-13.
  • 4Sweetman SC. Martindale The complete drug reference [B]. 36 ed. London, Chicago: Pharmaceutical Press, 2009.
  • 5荆志成.中国肺动脉高压治疗现状分析[EB/OL].http://www.365heart.eom/show/85245.shtml.2013-03-29.
  • 6Humbert M, Segal ES, Kiely DG, et al. Results of Eu- ropean post-marketing surveillance of bosentan in pul-monaty hypertension [J]. Eur Respir J, 2007, 30(2): 338-44.
  • 7Galie, N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hyper- tension, randomized, double-blind, placebo-controlled, nmlticenter, efficacy (ARIES) study 1 and 2[J]. Circula- tion, 2008. 117(23): 3010-9.
  • 8Galie N, et al. Ambrisentan therapy for pulmonary ar- terial hypertension [J]. JArn Coll Cardiol, 2005; 46: 529-35.
  • 9J Oudiz R J, Galie N, Olsehewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary ar- terial hypertension [J]. Am Coll Cardiol, 2009, 54(21): 1971-81.
  • 10Pulido T, Adzerikho I, Channick RN, et al. Maciten- tan and morbidity and mortality in pulmonary arterial hypertension[J]. N Engl J Med, 2013, 369(9): 809-18.

共引文献3

同被引文献21

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部